Morgan Stanley raised the firm’s price target on Idexx Laboratories (IDXX) to $805 from $765 and keeps an Overweight rating on the shares. Following a “strong” Q3 report and lifted 2025 guidance, the firm came away ” incrementally constructive,” the analyst tells investors. Following the report, the firm has “greater conviction in its growth prospects with one of the most compelling innovation pipelines in the company’s history,” the analyst added.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDXX:
- Idexx Laboratories price target raised to $750 from $710 at UBS
- Idexx Laboratories price target raised to $830 from $785 at BTIG
- Idexx Laboratories: Strong Financial Performance and Strategic Advancements Justify Buy Rating
- IDEXX Laboratories Reports Strong Q3 2025 Results
- Idexx Laboratories price target raised to $790 from $700 at BofA